Radioactive drug plus immunotherapy shows promise for tough lung cancer
NCT ID NCT07413042
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a combination of a radioactive drug ([225Ac]Ac-DOTATATE) and an immunotherapy (tislelizumab) as maintenance therapy for people with extensive-stage small cell lung cancer that has a specific marker (SSTR). The goal is to see if this combination is safe and can help keep the cancer from growing after initial treatment. About 24 adults who have finished their first round of standard chemotherapy will participate.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCLC, EXTENSIVE STAGE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University Cancer Hospital & Institute
RECRUITINGBeijing, Beijing Municipality, 100000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted drug combo outperform standard chemo for tough lung cancer?
- New drug cocktail aims to shrink tough lung cancers
- New drug cocktail aims at resistant lung cancer
- New drug combo aims to outperform standard care in aggressive lung cancer
- New hope for aggressive lung cancer: drug cocktail plus Low-Dose radiation shows promise
- New combo therapy targets tough lung cancer in early trial